Brainsway Ltd ADR(BWAY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | 47.81 | EPS (ttm) | 0.24 | Insider Own | 26.41% | Shs Outstand | 40.1M | Perf Week | 0.98% |
| Market Cap | 0.46B | Forward P/E | 22.42 | EPS next Y | 65.22% | Insider Trans | - | Shs Float | 29.6M | Perf Month | -9.84% |
| Enterprise Value | 0.40B | PEG | 0.51 | EPS next Q | 0.09 | Inst Own | 16.08% | Short Float | 0.76% | Perf Quarter | -28.15% |
| Income | 0.01B | P/S | 7.48 | EPS this Y | 70.37% | Inst Trans | 1.02% | Short Ratio | 2.1 | Perf Half Y | -32.54% |
| Sales | 0.06B | P/B | 5.76 | EPS next 5Y | 44.22% | ROA | 8.14% | Short Interest | 0.23M | Perf YTD | 19.45% |
| Book/sh | 1.97 | P/C | 7.33 | EPS past 3/5Y | - | ROE | 12.9% | 52W High | -34.71% ($17.40) | Perf Year | 33.73% |
| Cash/sh | 1.55 | P/FCF | 65.7 | Sales past 3/5Y | 24.82% 18.84% | ROIC | 11.17% | 52W Low | 59.22% ($7.14) | Perf 3Y | 580.24% |
| Dividend Est. | - | EV/EBITDA | 43.27 | EPS Y/Y TTM | 65.86% | Gross Margin | 75.32% | Volatility(W/M) | 4.2% 3.69% | Perf 5Y | 177.75% |
| Dividend TTM | - | EV/Sales | 6.58 | Sales Y/Y TTM | 31.63% | Oper. Margin | 12.47% | ATR (14) | 0.55 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.27 | EPS Q/Q | 25.36% | Profit Margin | 15.56% | RSI (14) | 40.92 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.59 | Sales Q/Q | 34.85% | SMA20 | -2.62% ($11.67) | Beta | 1.34 | Target Price | $19.27 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/11/10 | SMA50 | -12.31% ($12.95) | Rel Volume | 1.15 | Prev Close | $11.93 |
| Employees | 129 | LT Debt/Eq | 0.07 | EPS/Sales Surpr. | -4.5% 3.42% | SMA200 | -18.4% ($13.92) | Avg Volume(3M) | 0.11M | Price | $11.36 |
| IPO | 2019/4/17 | Option/Short | Yes/Yes | Trades | 1185 | Volume | 123,884 | Change | -4.78% |
BrainsWay (BWAY) is a global neuromodulation medical device company that develops Deep Transcranial Magnetic Stimulation (Deep TMS), a non-invasive neurostimulation therapy. Building on FDA clearance for indications such as major depressive disorder, the company provides non-drug treatment solutions in the fields of psychiatry and neurology.
Over the past 1 year, roughly in the middle
35% below its 1-year high.
Traded about as much as usual. That is 115% of its average volume.
Next earnings report: November 10
10 days to go.
BWAY makes money exceptionally well
Of every $100 in sales, $12.47 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +70.4% this year.
Tap to view numbers
However, it looks expensive
For a company earning $100 a year, you would pay $4,781. Peers typically go for $2,776.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +177.8%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 16.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #61 of 142 in the industry
Based on market cap of $457M.
DCTH#57 Delcath Systems Inc $487M PER 2301.6 
SSII#58 SS Innovations International Inc $471M PER - 
MASS#59 908 Devices Inc $465M PER - 
CERS#60 Cerus Corp $459M PER - BWAY#61 Brainsway Ltd ADR $457M PER 47.8 
FAQ
What kind of company is BWAY?
BWAY belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of BWAY?
The market cap of BWAY is approximately $457M, ranking 3,217 within its sector.
What is the P/E ratio of BWAY?
BWAY has a P/E ratio of approximately 47.8x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for BWAY?
BWAY has recorded a 52-week high of $17.40 and a low of $7.14.
